Concourse Financial Group Securities, Inc. Bionomics Limited Transaction History

Concourse Financial Group Securities, Inc.

$1.67 Billion
Q4 2024

13 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$0.44 - $0.84 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$0.69 - $1.2 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.89 - $1.38 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.13 - $4.46 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.95 - $3.37 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.95 - $3.37 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.96 - $2.9 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.8 - $4.7 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$4.65 - $9.67 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$6.0 - $9.12 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$6.5 - $9.97 $0 - $0
Q1 2022 May 09, 2022	BUY	$8.47 - $12.97 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$12.35 - $14.73 $0 - $0

Others Institutions Holding BNOX

# of Institutions

Shares Held

317K

Call Options Held

Put Options Held

View Full List

About BIONOMICS LIMITED

Ticker BNOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,518,620
Market Cap $24.4M
Description
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has ...

More about BNOX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account